Top Page
Scancell Holdings (SCLP) vs. S&P 500 (SPY)
Scancell Holdings Business Overview & Revenue Model
Scancell Holdings Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 5.27M | 0.00 | 0.00 | 0.00 | Gross Profit |
| -966.00K | 4.75M | -740.00K | -249.00K | -43.00K | EBIT |
| -18.27M | -11.92M | -13.30M | -8.83M | -6.78M | EBITDA |
| -7.06M | -12.19M | -3.75M | -14.90M | -6.72M | Net Income Common Stockholders |
| -5.86M | -11.94M | -2.06M | -15.48M | -5.51M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 14.82M | 19.92M | 41.11M | 3.58M | 4.56M | Total Assets |
| 23.58M | 30.27M | 49.06M | 8.82M | 10.54M | Total Debt |
| 19.87M | 19.53M | 15.46M | 129.00K | 129.00K | Net Debt |
| 5.05M | -387.00K | -25.66M | -3.45M | -4.43M | Total Liabilities |
| 27.08M | 36.50M | 29.57M | 1.17M | 1.21M | Stockholders Equity |
| -3.50M | -6.23M | 19.48M | 7.65M | 9.34M |
| Cash Flow | Free Cash Flow | |||
| -15.84M | -8.34M | -8.55M | -4.80M | -7.04M | Operating Cash Flow |
| -15.66M | -8.14M | -7.80M | -4.77M | -7.03M | Investing Cash Flow |
| 178.00K | 81.00K | -741.00K | -13.00K | 12.34K | Financing Cash Flow |
| 10.39M | -746.00K | 46.08M | 3.80M | 1.28M |
Scancell Holdings Technical Analysis
Scancell Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | £187.19B | 33.99 | 17.43% | 2.03% | 14.82% | 14.98% | |
70 Outperform | £62.51B | 24.29 | 19.06% | 3.98% | 3.46% | -48.06% | |
49 Neutral | $7.05B | 0.34 | -55.09% | 2.46% | 25.27% | -3.43% | |
35 Underperform | £87.61M | ― | 167.16% | ― | -100.00% | -23.91% |
Scancell Holdings Corporate Events
Scancell Holdings plc has announced the issuance of share options to its executive directors as part of the company’s long-term incentive plan. The options, granted to CEO Phil L’Huillier, CSO Lindy Durrant, and CFO Sath Nirmalananthan, are intended to incentivize and retain key personnel. The options, which have an exercise price of 11.7 pence each, will vest over three years and represent a significant portion of the company’s issued share capital. This strategic move aims to align the interests of the executive team with those of shareholders and fortify Scancell’s positioning in the competitive biopharmaceutical industry.
Scancell Holdings plc announced that translational data from its ongoing Phase 2 SCOPE trial of SCIB1, a DNA plasmid melanoma cancer vaccine, will be presented at the AACR IO conference. The data showcases the efficacy of SCIB1 when combined with nivolumab and ipilimumab, demonstrating an 84% disease control rate and 80% progression-free survival in late-stage melanoma patients. This presentation is expected to validate SCIB1’s potential in cancer immunotherapy, potentially strengthening Scancell’s position in the industry and offering new hope for stakeholders, including patients and investors.
Scancell Holdings plc reported strong clinical and organizational progress in its interim results for the six months ending 31 October 2024. The company’s lead cancer vaccine, SCIB1, showed impressive results in advanced melanoma trials, and the next-generation iSCIB1+ and Modi-1 vaccines are advancing well, with promising outcomes in other cancer studies. Strategic partnerships and recent financial activities, including a capital raise of £11.3 million, strengthen Scancell’s position to achieve key clinical milestones in 2025, ensuring continued innovation and development in cancer treatment.
Scancell Holdings plc announced that it will release its interim results for the six months ended October 31, 2024, on January 30, 2025. The announcement will be accompanied by a virtual analyst briefing and a live webcast with a Q&A session. This could potentially impact stakeholders by providing updated insights into the company’s progress and future outlook in the biopharmaceutical industry.
Scancell Holdings has achieved early clinical validation for its Modi-1 Moditope® vaccine in treating HPV-negative head and neck squamous cell carcinoma, showing a partial response in 43% of patients compared to lower historical rates with standard treatments. This success, along with new patent approval in the US, enhances the commercial positioning of Modi-1 Moditope®, potentially improving the company’s competitiveness in the cancer vaccine market.
Scancell Holdings has successfully raised approximately £11.3 million through a significantly oversubscribed retail offer and capital raise, priced at 10.5 pence per share. This financial boost, involving the issuance of 9,523,809 new ordinary shares, attracted considerable interest from both existing and new healthcare specialist investors. The new shares are set to be traded on AIM, increasing the company’s total voting rights to over 1 billion shares.
Scancell Holdings Plc has successfully raised £10.3 million through an oversubscribed placing, which attracted substantial interest from existing and new healthcare specialist investors. The funds will support the development of its cancer vaccine, SCIB1, and its next-generation counterpart, iSCIB1+, as the company strives to advance its clinical trials for treating advanced melanoma. This financial boost is set to extend Scancell’s cash runway into the second half of 2026, signaling robust investor confidence in its innovative immunotherapy solutions.